Novartis Allays Concerns Over Cosentyx Sales Miss

The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.

Panic button
No need to panic: Novartis confident about Cosentyx future • Source: Shutterstock

Eyebrows have been raised over the first-quarter performance of Novartis AG's psoriasis blockbuster Cosentyx (secukinumab) but the company has stressed that the drug is making major advances as first-line therapy in dermatology but more strikingly in its rheumatology indications.

Although sales of $580m, up 35% on the like, year-earlier period, looks like a decent return, Cosentyx revenues were 9%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.